CG Oncology (CGON) vs Tango Therapeutics (TNGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tango Therapeutics (TNGX) has outperformed CG Oncology (CGON) over the past year, gaining 199.5% versus a gain of 64.2%. CG Oncology is the larger company by market cap ($5.48 billion vs $3.59 billion), about 1.5 times the size. Tango Therapeutics converts more of its revenue into profit, with a net margin of -162.9% versus -3985.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGON | TNGX |
|---|---|---|
| Share price | $61.84 | $21.29 |
| Market cap | $5.48B | $3.59B |
| 1-day change | -0.87% | -2.47% |
| YTD return | +50.24% | +146.39% |
| 1-year return | +64.16% | +199.45% |
| 5-year return | — | +55.60% |
| EPS (TTM) | $-2.69 | $-0.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.04M | $62.38M |
| Revenue growth (YoY) | +254.70% | +48.29% |
| Net income (latest FY) | $-161.00M | $-101.59M |
| Operating margin | -4722.13% | -178.39% |
| Net margin | -3985.02% | -162.85% |
| 52-week high | $80.97 | $34.39 |
| 52-week low | $35.80 | $6.69 |
| Distance from 52-week high | -23.63% | -38.09% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +47.28% | +112.21% |
| Average volume | 887.57K | 2.61M |
| Shares outstanding | 88.64M | 168.61M |
| Employees | 142 | 137 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TNGX has outperformed CGON by 135.3 percentage points over the past year.
- Tango Therapeutics is more profitable, keeping -162.9 cents of every revenue dollar as net income versus -3985.0 cents for CG Oncology.
- CG Oncology grew revenue faster in its latest fiscal year (+254.70% vs +48.29%).
About CG Oncology
CGON stock →CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
About Tango Therapeutics
TNGX stock →Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 137 employees
CGON vs TNGX FAQ
Which is bigger, CG Oncology or Tango Therapeutics?
CG Oncology (CGON) is larger, with a market capitalization of $5.48B compared with $3.59B for Tango Therapeutics (TNGX).
Which stock has performed better over the past year, CGON or TNGX?
TNGX returned +199.45% over the past 12 months, compared with +64.16% for CGON (price return, excluding dividends). Past performance does not predict future results.
Are CG Oncology and Tango Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for CG Oncology and Biotechnology: Pharmaceutical Preparations for Tango Therapeutics.